Drugs / OBEROTATUG RAVTANSINE
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05930951 | Nov 2023 → Oct 2024 | adenoid cystic carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Terminated | No outcome recorded |
| Phase 1 | NCT04064359 | Jul 2019 → Dec 2026 expected | cancer | Oxford BioTherapeutics Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT03403725 | Aug 2017 → Oct 2019 | metastatic neoplasm, non-Hodgkin lymphoma | Menarini Group | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBEROTATUG RAVTANSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314757 ↗ |
| Known as | MEN1309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03403725 ↗ |
| Known as | Oberotatug ravtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314757 ↗ |
| Known as | OBT076 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05930951 ↗ |
| Action | Deplete | “OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them.” NCT04064359 ↗ |
| Modality | Other / unclassified | “CD205 Antibody-Drug Conjugate” NCT03403725 ↗ |
| Route | Intravenous | “intravenous infusion” NCT03403725 ↗ |
| Target | LY75 | “antibody directed against the CD205/Ly75 antigen (MBH1309)” NCT05930951 ↗ |